Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Ingalls Industries Inc (HII) vs Revvity Inc (RVTY) Price & Performance

Huntington Ingalls Industries IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Huntington Ingalls Industries Inc vs Revvity Inc — how do they compare? Huntington Ingalls Industries Inc trades at $277.03 (market cap $10.59B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.05%). Which is the better fit depends on your goals.

HIIRVTY
Market Cap
$10.59B$12.33B
Sector
TechnologyTechnology
52-Week High
$453.73$117.75
52-Week Low
$253.96$82.26
Enterprise Value
$13.31B$14.82B
Dividend Yield
2.05%0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Ingalls Industries Inc

HII trades at $270.04, up 0.34% with a bearish technical signal despite recent earnings beats. The company maintains stable revenue around $12.5B with 4.71% net margins and attractive valuation metrics including P/E of 17.55 and P/S of 0.83. Recent developments include key shipbuilding milestones and unmanned vehicle contract awards, while analyst consensus shows 44% buy ratings with a $354.50 price target.

HII presents a mixed outlook with strong fundamentals and analyst optimism offset by bearish technical indicators. The stock offers value with below-market valuation multiples and consistent government contract flow, but faces execution risks in defense spending cycles and competitive pressures. Near-term catalyst includes Q2 2026 earnings on July 30, with current price representing 24% discount to consensus target.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY